No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 15 of the 40 quarters in the window, leaving 25 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 12.7x · 10Y median 27.7x · 30th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:45:14.060Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T12:45:14.060Z. Latest historical point 2025-08-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T12:45:14.060Z. Latest historical point 2025-08-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:45:14.060Z. Latest historical point 2025-08-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T12:45:14.060Z. Latest historical point 2025-08-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for AC Immune S.A. (ACIU) stock was $2.71 as of Oct 5, 2026, 4:00 PM EDT, down 0.55% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -31.9% · 3-year avg +2.9%/yr · 5-year avg -16.0%/yr
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools.
Biotechnology · Lausanne, VD
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-0.22
Revenue Est.
$328683.00
Last Quarter Results
EPS
$0.02
vs Estimate
$-0.11
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ACIU | $275.81M | $2.71 | -0.55% | -31.95% | -16.03% | -16.61% | N/A |
| 2ACB | $276.26M | $4.46 | +13.78% | -20.97% | -42.83% | -30.23% | vs ACIU |
| 3FULC | $283.06M | $3.71 | +0.54% | -59.59% | -31.70% | N/A | vs ACIU |
| 4FATE | $283.24M | $2.43 | +4.74% | +100.16% | -46.86% | -2.31% | vs ACIU |
| 5EYPT | $264.10M | $3.15 | -3.08% | -76.90% | -21.68% | -20.02% | vs ACIU |
| 6IKT | $264.07M | $2.00 | +0.00% | +20.37% | -29.10% | N/A | vs ACIU |
forward FY estimate
N/A
$15.18M
vs Estimate
$34.08M
Consensus Rating
Based on 4 analysts
Average Price Target
$8.52
+214.6% upside
Low
$5.35
Current
$2.71
High
$11.89
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CHF -0.15 | CHF -0.15 | CHF -0.15 | 1 |
| Quarter ending Dec 2026 | CHF -0.14 | CHF -0.14 | CHF -0.14 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CHF -0.56 | CHF -0.42 | CHF -0.33 | 2 |
| FY 2027 | CHF 0.16 | CHF 0.20 | CHF 0.27 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | CHF 273472.00 | CHF 273472.00 | CHF 273472.00 | 2 |
| Quarter ending Dec 2026 | CHF 1.95M | CHF 1.95M | CHF 1.95M | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CHF 17.03M | CHF 20.29M | CHF 25.54M | 2 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| FY 2027 |
| CHF 100.25M |
| CHF 119.43M |
| CHF 150.32M |
| 3 |
